Related Experiment Videos
Paroxysmal supraventricular tachycardia: experience with propafenone
V Santinelli1, M De Paola, P Turco
1Department of Cardiology and Cardiac Surgery, University of Naples, Italy.
Angiology
|June 1, 1989
Summary
Propafenone effectively controls supraventricular tachycardia (SVT). Intravenous (IV) propafenone stops SVT immediately and predicts oral therapy success, with minimal side effects.
Area of Science:
- Cardiology
- Clinical Pharmacology
Background:
- Recurrent supraventricular tachycardia (SVT) poses a significant clinical challenge.
- Wolff-Parkinson-White syndrome is a common cause of SVT.
Purpose of the Study:
- To evaluate the efficacy of intravenous (IV) and oral propafenone in patients with paroxysmal SVT.
- To determine if IV propafenone can predict oral therapy response.
Main Methods:
- 16 patients with paroxysmal SVT received either IV or oral propafenone.
- Efficacy assessed by ability to stop or prevent SVT induction via transesophageal pacing.
- Dosage titration for oral propafenone was performed.
Main Results:
- IV propafenone terminated or prevented SVT in 9/11 patients.
- Oral propafenone prevented SVT induction in 3/5 patients initially.
- In patients responsive to IV propafenone, oral therapy was effective, with 600 mg/day being the minimum effective dose for most.
- No major side effects were reported.
Conclusions:
- Propafenone is highly effective for controlling paroxysmal SVT.
- IV propafenone administration serves as a reliable predictor of oral propafenone efficacy.
- Propafenone offers a safe and effective treatment option for SVT management.